Cardiff Lexington 3Q 2026: Revenue $1.91M, EPS ($0.22) — 10-Q Summary
Cardiff Lexington reported 3Q 2026 revenue of $1.91M, down 37.5% YoY, and a net loss of $3.5M, widened from $1.41M. EPS was ($0.22). Declines were attributed to fewer healthcare procedures and lower settlement rates. Gross margin fell to 54.22% from 62.43%.
How this was made
The 30-second read
Why it matters
The earnings shortfall is likely to trigger a sell‑off in the thinly‑traded stock.
Market read
Micro‑cap investors will reassess exposure; broader market impact is negligible.
What to watch
Potential cost reductions in SG&A could improve margins if revenue stabilizes.
Background
Cardiff Lexington Corp (CDIX) filed its Q3 2026 10‑Q, reporting a steep revenue decline and widened loss.
Ticker impact
Q3 2026 10‑Q shows revenue down 37.5% YoY to $1.91M and net loss widening to $3.5M.
likely downward pressure as investors price in weaker performance
The filing reveals a material decline in revenue and a sharp increase in net loss, which are fresh, material facts for a micro‑cap.
Market effects
Highlights weakness in the niche healthcare services sector.
Limited to investors in US micro‑caps.
Minimal.
Counterpoint
If the company can stabilize settlement rates, the stock may be undervalued after the sell‑off.
Key entities
- CompanyCardiff Lexington Corp
Micro‑cap healthcare services firm reporting Q3 results.
